close

September 2021

Medical products

Operations | Medtech | Pharmaceutical and medical products

We offer a suite of proprietary tools and methodologies to optimize technical systems, develop management infrastructures and promote good behavior and mentality. Here are examples of some of these tools we use to complement our work:

Comparative analysis of medical devicesMT: Diagnostic and transformation tool for manufacturing, supply chain, quality, purchasing and organization, with over 50 customizable metrics per module that give insightful recommendations for actionable opportunities.

Model factories: A global network of nine Capacity Centers that provide over 150 online and in-person leadership and skills development training in product development, procurement, supply chain management, service operations and performance management. Learn more about model factories.

Suite of complexity management solutions: A diagnostic suite using advanced analytics to assess the complexity of a medical technology firm’s portfolio and the in-game value of optimizing and improving management, and provide actionable recommendations. It includes tools like Complexity Fingerprint, Wallet X-ray, Complexity Cost Calculator, Wallet Setup, and Complexity Cockpit.

Design to Value (DtV) and Cleansheet Solution ™ Laboratories: Our engineering centers of expertise where competitive product teardowns and cost modeling are performed to strengthen customer focus and help reduce time to market and product costs. Our Cleansheet Solution ™ helps establish cost transparency, analyze cost drivers, calculate target cost and reap those benefits. Learn more about Design to Value and Cleansheet Solution.

Purchasing centers: Our global sourcing centers located in Brazil, China, Eastern Europe, India and Mexico using our Global Sourcing Information Exchange (GSIE) database help identify suppliers in low cost countries. Learn about innovation, design and development, productivity, agility and automation, and quality, compliance and remediation.

read more
Medical products

Baxter to Acquire Hillrom in $ 10.5 Billion Medicines Deal | Illinois News

DEERFIELD, Ill. (AP) – Medicines company Baxter International will acquire medical technology company Hillrom for $ 10.5 billion in cash, the companies said Thursday. Baxter will also absorb Hillrom’s debt and cash, bringing the total value of the transaction to $ 12.4 billion.

Baxter will pay Hillrom shareholders $ 156 per share a 26% premium over its July 27 closing price when speculation about a deal began to rise. Hillrom shares closed at $ 145.06 on Thursday and rose more than 3% in pre-market trading, to $ 149.75.

Baxter, based in Deerfield, Ill., Which offers essential hospital products including dialysis, intravenous fluids and other therapies and devices, had sales of $ 11.7 billion in 2020, with expected sales of $ 12.6 billion this year.

Hillrom, headquartered in Chicago, focuses on medical technology products and services such as smart beds, patient monitoring and diagnostic technologies, and advanced surgical equipment. Its turnover is approaching $ 3 billion per year.

Political cartoons

The deal was reached by the boards of directors of both companies and is expected to be finalized in early 2022, pending regulatory approval and a vote by Hillrom shareholders.

Baxter shares rose about 1% in pre-market trading, to $ 78.40.

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

read more
Medical products

Advancing next-generation medical products

Photos courtesy of Avient Corporation, © 2021

An aging population and the growing threat of emerging infectious viral diseases, such as COVID-19, mean that global healthcare is an extremely important problem and is changing dramatically and dynamically. To respond to these changes, a new generation of specialized and sustainable medical equipment solutions is emerging. Read on to learn more about the evolution of this industry and to explore an example of medical device innovation.

If you haven’t seen a doctor in person since the onset of the coronavirus pandemic, you are not alone. Telemedicine and on-demand care have exploded over the past 12 months and are two of many growing trends in global healthcare. Another trend in the era of increasing personalized medicine is the development of biologic pharmaceuticals. A rapidly growing market, the revenues of biologic pharmaceutical companies have increased by 70% over the past five years, to more than US $ 232 billion.[i]. Yet the high doses required by patients for biologic therapies can present very real challenges for drug delivery.[ii]. Whatever the trend and in all directions in which healthcare develops, the goal is always to protect and improve the lives of patients.

Plastics in medical devices and pharmaceutical packaging increasingly play a vital role in providing safe treatments and their use is expected to increase further. This can be attributed to the fact that they offer design freedom, protection, convenience and functionality that few other materials can match. Globally in 2020, approximately 7.6 million tonnes of plastics were used in healthcare applications[iii] and this is expected to grow by around 8.6% from 2020 to 2027. Companies supplying plastics to the healthcare market must have in-depth knowledge of the industry, as well as advanced technical and design capabilities, to develop innovative solutions that truly respond to their customers. challenges.

Let’s take a look at an example of an innovative solution – a conceptual auto-injector, where the new generation meets industry trends for the functionality and aesthetics of surfaces.

Auto-injectors are a great example of innovation, bringing more convenience and control to the lives of patients. Playing on trends in telemedicine, on-demand care and biologics, they offer self-management and drug administration, technology-driven monitoring and diagnostics, as well as the ability to deliver increased volumes of drugs. and large molecule biologics.

This study example describes a conceptual auto-injector developed by Avient – a new materials company born from two historical leaders, PolyOne and Clariant Masterbatch. It will illustrate how Avient has used innovative materials, design and technological services to accelerate the development of next generation products.

Photos courtesy of Avient Corporation, © 2021

The injection window and cap of an autoinjector require excellent clarity, scratch resistance, and exceptional toughness for visualizing drug levels. In this study, an anti-UV additive was used to protect the drug contents from harmful UV rays without sacrificing clarity or transparency. Next, a dynamic masterbatch formulation (MEVOPUR ™ medical grade dyes) was used to enable product differentiation, better drug identification and consistent branding. MEVOPUR colors highlight the cap, button, lot ID / SKU, trigger and plunger. The raw materials were tested against common pharmaceutical standards to ensure that the devices would be safe and compliant from a regulatory point of view.

On the body of the autoinjector, a laser marking additive has been used to enable inkless marking, with no surface pretreatment required, thus avoiding solvent residue. The additive provided reliability and process improvement over traditional marking technologies and improved design possibilities due to the absence of physical contact with the marking system. This type of laser marking functionality can be combined with other functions or dyes to meet performance and aesthetic needs. In addition, to combat the increase in counterfeit drugs and devices in the healthcare industry, Avient has also developed a comprehensive plastic solution that protects against counterfeiting, while enabling medical device companies to ensure the integrity. supply chain with low impact on productivity and operations.

For the integrated rigid needle guard and device cap, biocompatibility, durability and overmolding are essential. A medical grade TPE (Versaflex ™ HC TPE) replaced rubber, with sealing properties to prevent needle contamination and oxygen contact with drugs in pre-filled syringes. These TPEs are USP VI tested and chemical resistant with low extractability and no tearing.

The viscosity of the drug has a direct impact on the pain of patients during drug administration. Therefore, the device’s heating system and heat exchanger used thermally conductive formulations to help heat and reduce the viscosity of biologic drugs.

Technology is transforming the way care is delivered by making it simpler, easier, more collaborative and more data-driven. This conceptual auto-injector is a demonstration of how next-generation materials and design expertise can truly improve a finished device.

If you would like more information on this application study, or on Avient materials and colorant / additive technologies, please visit avient-help.com.


[i] https://www.iqvia.com/-/media/iqvia/pdfs/nemea/uk/disruption_and_maturity_the_next
_phase_des_biologics.pdf
[ii] https://pubmed.ncbi.nlm.nih.gov/26277263/
[iii] https://www.grandviewresearch.com/industry-analysis/medical-plastics-market

Content sponsored by Avient Corporation

read more